CHMP Issues Positive Opinion for ORENCIA® (abatacept) in the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis not Previously Treated with Methotrexate in the EU If approved for the new indication, ORENCIA would be the first biologic therapy with an EU indication specifically applicable to the treatment of MTX-naive RA patients with highly active and progressive disease Would mark the first time that MRI assessment of structural and inflammatory measures of disease severity are cited in SmPC to support an RA indication Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...
↧